bioAffinity Technologies, Inc. - 8-K Filing
On May 12, 2026, bioAffinity Technologies reported that unit sales for its CyPath® Lung diagnostic test reached a record high in April 2026 and increased nearly 300% compared to the same period in 2025. The growth reflects accelerating physician adoption of the noninvasive lung cancer detection tool. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $BIAF